This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: February 23, 2006
Last updated: December 12, 2007
Last verified: December 2007
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

Condition Intervention Phase
Acute Coronary Syndrome Drug: Rosuvastatin Drug: Atorvastatin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percentage changes in ApoB/ApoA-I levels [ Time Frame: from Day 0 to 3 months ]

Secondary Outcome Measures:
  • Percentage changes in LDL-C [ Time Frame: from Day 0 to 1 month and 3 months ]
  • Percentage changes in the hs-CRP and AUC of hs-CRP levels [ Time Frame: from Day -6 to Day 0 ]
  • Percentage changes in ApoA-I [ Time Frame: from Day 0 to 1 month ]

Estimated Enrollment: 1160
Study Start Date: January 2006
Study Completion Date: October 2007

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
  • Percutaneous coronary intervention (PCI) planned,
  • Evidence of coronary artery disease

Exclusion Criteria:

  • Hypersensitivity to statins
  • Any cholesterol lowering medication taken within 1 month prior V1
  • Sustained ST-segment elevation on ECG
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00296387

  Show 102 Study Locations
Sponsors and Collaborators
Study Director: AstraZeneca France Medical Director, MD AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00296387     History of Changes
Other Study ID Numbers: D3560L00052
Study First Received: February 23, 2006
Last Updated: December 12, 2007

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Atorvastatin Calcium
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on September 19, 2017